Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$11.11 - $25.6 $12 Million - $27.8 Million
-1,084,417 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$11.75 - $21.42 $12.7 Million - $23.2 Million
1,084,417 New
1,084,417 $13.8 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Cpv Partners, LLC Portfolio

Follow Cpv Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cpv Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cpv Partners, LLC with notifications on news.